Search Results for: biotechnolog

OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

- Option to in-license and develop small molecule leads against a novel target for the treatment of fibrotic diseases - Strengthens pipeline and reinforces OncoArendi’s strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) 11

Read more

OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board  

New members to bring additional scientific, operational and HR expertise  Warsaw, Poland – 31 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to

Read more

OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer

Dr. Fung to Lead Global Clinical Development, Translational Science and Regulatory Strategies Warsaw, Poland – 27 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal

Read more

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members Appointments bring global leadership experience and expertise in drug discovery, as well as clinical

Read more

OncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms

According to the strategy released in March, OncoArendi Therapeutics S.A. (WSE: OAT) expands its existing innovative drug discovery platforms by launching two new programs: CHIT1 SELECTIVE focusing on new therapeutic areas within the chitinase platform and

Read more

OncoArendi executes the strategy for 2021-2025 in the area of R&D platform for developing small molecules modulating RNA function

· On June 16 2021, the Company signed a scientific cooperation agreement with the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) in the field of discovery and development of small molecule drugs modulating

Read more

OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis

Mechelen, Belgium and Warsaw, Poland, 5 November 2020, 22:15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that they have signed an exclusive collaboration and license agreement for the

Read more

OncoArendi Therapeutics expands the therapeutic potential of its Chitinase Platform

OncoArendi develops OATD-01 as a drug candidate for treatment of severe inflammatory and fibrotic diseases. Clinical trials in patients must be preceded by a number of preclinical safety studies, including GLP standard chronic toxicology. Such studies,

Read more

OncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01

the report confirms the OATD-01 safety profile which justifies further clinical development of this experimental drugIn Q1 of 2021 the company plans to file for an approval of the next phase clinical trial in sarcoidosis patients

Read more